Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome-Reference-Cited by-同舟云学术

Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Published:2012-08-08 Issue:6 Volume:189 Page:3198-3208
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Mailloux Adam W.,Sugimori Chiharu,Komrokji Rami S.,Yang Lili,Maciejewski Jaroslaw P.,Sekeres Mikkael A.,Paquette Ronald,Loughran Thomas P.,List Alan F.,Epling-Burnette Pearlie K.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference48 articles.

1. Swerdlow S. International Agency for Research on Cancer World Health Organization . 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France.

2. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.;Germing;Haematologica,2006

3. Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making

4. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

5. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium;HemaSphere;2024-05

2. Physiopathologie des syndromes myélodysplasiques;Bulletin du Cancer;2023-11

3. Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications;Diagnostics;2022-07-07

4. Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia;Diseases;2022-06-10

5. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma;Molecular Therapy;2022-06